WELCOME TO The Biotechnology REPORT
Atossa Genetics, Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
PDS Biotechnology | October 04, 2022
PDS Biotechnology Corporation a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® for the treatment of unresectable, recurrent/metastatic human papilloma virus 16-positive head and neck squamous cell carcinoma.
INDUSTRIAL IMPACT, MEDICAL
Globenewswire | March 31, 2023
Omega Therapeutics, Inc. a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma (HCC), in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase 1/2 MYCHELANGELO™ I clinical trial.
Abveris, Biosciences | November 12, 2021
Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases.
Under this partnership agreem...
CELL AND GENE THERAPY
Neurophth | January 19, 2021
Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy.
AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE